In Vivo CAR-T: Technology Landscape, Clinical Evidence and Strategic Transactions
In Vivo CAR-T Paradigm
In vivo CAR-T seeks to move cell therapy from individualized ex vivo manufacturing toward direct immune-cell engineering inside the patient. Genetic payloads are delivered systemically to program endogenous immune cells in situ, potentially reducing manufacturing complexity, treatment delays and the need for lymphodepletion. The principal technical challenge shifts from manufacturing the cell product to achieving selective delivery, sufficient transduction, expansion and persistence in vivo.
What the Attached Market Review Covers
Strategic transactions: Recent acquisitions, licensing agreements and collaborations involving Lilly, AbbVie, AstraZeneca, Gilead/Kite, BMS, J&J and others.
Technology landscape: Targeted lentiviral vectors, linear mRNA/LNP, circular or endless RNA, integrative non-viral systems and alternative delivery approaches.
Technology trade-offs: Integrating versus non-integrating platforms, with different profiles for persistence, repeat dosing and genomic modification.
Indication positioning: Why durable integrating approaches may be more relevant in oncology while transient RNA-based approaches may have a different role in autoimmune disease.
Clinical evidence: Early human data from Legend Biotech’s LB2501, Lilly/Kelonia’s KLN-1010 and EsoBiotec/AstraZeneca’s ESO-T01, including response, CAR-T expansion, persistence, lymphodepletion and safety observations.